P. Jonathan Foster's most recent trade in Moleculin Biotech Inc was a trade of 810,810 Series E Warrants done . Disclosure was reported to the exchange on June 20, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Moleculin Biotech Inc | Jonathan P. Foster | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 20 Jun 2025 | 810,810 | 1,038,320 | - | - | Series E Warrants | |
| Moleculin Biotech Inc | Jonathan P. Foster | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.37 per share. | 20 Jun 2025 | 270,270 | 287,587 (0%) | 0% | 0.4 | 100,000 | Common Stock |
| Moleculin Biotech Inc | Jonathan P. Foster | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jun 2025 | 4,328 | 18,371 (0%) | 0% | - | Common Stock | |
| Moleculin Biotech Inc | Jonathan P. Foster | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jun 2025 | 4,328 | 227,510 | - | - | Restricted Stock Units | |
| Moleculin Biotech Inc | Jonathan P. Foster | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jun 2025 | 2,711 | 231,838 | - | - | Restricted Stock Units | |
| Moleculin Biotech Inc | Jonathan P. Foster | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jun 2025 | 2,711 | 14,704 (0%) | 0% | - | Common Stock | |
| Moleculin Biotech Inc | Jonathan P. Foster | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.27 per share. | 20 Jun 2025 | 1,054 | 17,317 (0%) | 0% | 0.3 | 281 | Common Stock |
| Moleculin Biotech Inc | Jonathan P. Foster | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.27 per share. | 20 Jun 2025 | 661 | 14,043 (0%) | 0% | 0.3 | 176 | Common Stock |
| Moleculin Biotech Inc | Jonathan P. Foster | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2025 | 833 | 12,196 (0%) | 0% | - | Common Stock | |
| Moleculin Biotech Inc | Jonathan P. Foster | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2025 | 833 | 230,684 | - | - | Restricted Stock Units | |
| Moleculin Biotech Inc | Jonathan P. Foster | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.68 per share. | 16 Jun 2025 | 203 | 11,993 (0%) | 0% | 0.7 | 139 | Common Stock |
| Moleculin Biotech Inc | Jonathan P. Foster | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Oct 2024 | 82,500 | 212,337 | - | - | Restricted Stock Units | |
| Moleculin Biotech Inc | Jonathan P. Foster | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Oct 2024 | 65,000 | 129,837 | - | - | Stock option (right to buy) | |
| Moleculin Biotech Inc | Jonathan P. Foster | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Oct 2024 | 19,180 | 231,517 | - | - | Performance Based Restricted Stock Units | |
| Moleculin Biotech Inc | Jonathan P. Foster | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jun 2024 | 4,329 | 12,416 (0%) | 0% | - | Common Stock | |
| Moleculin Biotech Inc | Jonathan P. Foster | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jun 2024 | 4,329 | 64,837 | - | - | Restricted Stock Units | |
| Moleculin Biotech Inc | Jonathan P. Foster | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.74 per share. | 22 Jun 2024 | 1,053 | 11,363 (0%) | 0% | 3.7 | 3,938 | Common Stock |
| Moleculin Biotech Inc | Jonathan P. Foster | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jun 2024 | 2,712 | 69,166 | - | - | Restricted Stock Units | |
| Moleculin Biotech Inc | Jonathan P. Foster | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jun 2024 | 2,712 | 8,723 (0%) | 0% | - | Common Stock | |
| Moleculin Biotech Inc | Jonathan P. Foster | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.78 per share. | 20 Jun 2024 | 636 | 8,087 (0%) | 0% | 3.8 | 2,404 | Common Stock |
| Moleculin Biotech Inc | Jonathan P. Foster | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2024 | 834 | 6,207 (0%) | 0% | - | Common Stock | |
| Moleculin Biotech Inc | Jonathan P. Foster | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2024 | 834 | 71,878 | - | - | Restricted Stock Units | |
| Moleculin Biotech Inc | Jonathan P. Foster | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.14 per share. | 16 Jun 2024 | 196 | 6,011 (0%) | 0% | 4.1 | 811 | Common Stock |
| Moleculin Biotech Inc | P. Jonathan Foster | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.69 per share. | 26 Dec 2023 | 28,986 | 80,556 (0%) | 0% | 0.7 | 20,000 | Common Stock |
| Volcon Inc | Jonathan P. Foster | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jul 2023 | 200,000 | 376,250 | - | - | Stock Option | |
| Moleculin Biotech Inc | Jonathan P. Foster | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2023 | 259,688 | 1,090,626 | - | - | Restricted Stock Units | |
| Moleculin Biotech Inc | Jonathan P. Foster | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2023 | 150,000 | 830,938 | - | - | Stock option (right to buy) | |
| Moleculin Biotech Inc | Jonathan P. Foster | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2023 | 40,667 | 680,938 | - | - | Restricted Stock Units | |
| Moleculin Biotech Inc | Jonathan P. Foster | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2023 | 40,667 | 61,246 (0%) | 0% | - | Common Stock | |
| Moleculin Biotech Inc | Jonathan P. Foster | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2023 | 12,500 | 23,623 (0%) | 0% | - | Common Stock | |
| Moleculin Biotech Inc | Jonathan P. Foster | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2023 | 12,500 | 721,605 | - | - | Restricted Stock Units | |
| Moleculin Biotech Inc | Jonathan P. Foster | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.57 per share. | 16 Jun 2023 | 9,676 | 51,570 (0%) | 0% | 0.6 | 5,515 | Common Stock |
| Moleculin Biotech Inc | Jonathan P. Foster | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.57 per share. | 16 Jun 2023 | 3,044 | 20,579 (0%) | 0% | 0.6 | 1,735 | Common Stock |
| Volcon Inc | Jonathan P. Foster | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2022 | 101,250 | 176,250 | - | - | Stock Option | |
| Moleculin Biotech Inc | Jonathan P. Foster | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2022 | 162,667 | 734,105 | - | - | Restricted Stock Units | |
| Moleculin Biotech Inc | Jonathan P. Foster | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2022 | 155,000 | 571,438 | - | - | Stock option (right to buy) | |
| Moleculin Biotech Inc | Jonathan P. Foster | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2022 | 12,500 | 14,167 (0%) | 0% | - | Common Stock | |
| Moleculin Biotech Inc | Jonathan P. Foster | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2022 | 12,500 | 416,438 | - | - | Restricted Stock Units | |
| Moleculin Biotech Inc | Jonathan P. Foster | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.33 per share. | 16 Jun 2022 | 3,044 | 11,123 (0%) | 0% | 1.3 | 4,049 | Common Stock |
| Moleculin Biotech Inc | Jonathan P. Foster | Exec. Vice President and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 108,770 | 378,938 | - | - | Stock option (right to buy) | |
| Moleculin Biotech Inc | Jonathan P. Foster | Exec. Vice President and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 50,000 | 428,938 | - | - | Restricted Stock Units |